Mr. Puneet Khanna reports

CARERX CORPORATION RECEIVES REGULATORY APPROVAL FOR LAUNCH OF ITS NORMAL COURSE ISSUER BID

The Toronto Stock Exchange (the TSX) has approved CareRx Corp.'s previously announced normal course issuer bid (the NCIB) to purchase for cancellation up to one million of its common shares, representing approximately 1.73 per cent of its 57,743,726 issued and outstanding shares as at Aug. 31, 2023.

It is expected that the NCIB will begin on Sept. 7, 2023, and will end on Sept. 6, 2024. Daily purchases on the TSX under the NCIB will be limited to 4,624 shares, other than purchases made pursuant to the block purchase exception, being 25 per cent of the average daily trading volume on the TSX for the six months ending July 31, 2023. The actual number of shares to be purchased, and the timing of any such purchases, will be determined by the company, subject to the applicable rules and policies of the TSX. All shares acquired will be cancelled.

Although the company presently intends to purchase shares under its NCIB, there can be no assurances that any such purchases will be completed. The purchases will be made through the facilities of the TSX and/or any alternative trading system in Canada. The company will pay the market price for the common shares at the time of acquisition and the purchases will be made in accordance with applicable regulatory requirements.

About CareRx Corp.

CareRx is Canada's leading provider of pharmacy services to seniors living communities. The company serves over 95,000 residents in over 1,500 seniors and other congregate care communities (long-term care homes, retirement homes, assisted living facilities and group homes). The company is a national organization with a large network of pharmacy fulfilment centres strategically located across the country. This allows the company to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. The company uses best-in-class technology that automates the preparation and verification of multidose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. The company takes an active role in working with its home operator partners to promote resident health, staff education, and medication system quality and efficiency.

We seek Safe Harbor.